David Caudell to Enzyme Inhibitors
This is a "connection" page, showing publications David Caudell has written about Enzyme Inhibitors.
Connection Strength
0.241
-
Cook GJ, Caudell DL, Elford HL, Pardee TS. The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML. PLoS One. 2014; 9(11):e112619.
Score: 0.115
-
Pardee TS, Gomes E, Jennings-Gee J, Caudell D, Gmeiner WH. Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity. Blood. 2012 Apr 12; 119(15):3561-70.
Score: 0.095
-
Regna NL, Vieson MD, Luo XM, Chafin CB, Puthiyaveetil AG, Hammond SE, Caudell DL, Jarpe MB, Reilly CM. Specific HDAC6 inhibition by ACY-738 reduces SLE pathogenesis in NZB/W mice. Clin Immunol. 2016 Jan; 162:58-73.
Score: 0.031